Orthocell (ASX:OCC) has reported that its Remplir nerve repair device has been used in 23 surgical procedures on Ukrainian soldiers in combat, marking a significant real-world application of the company’s regenerative medicine technology in a conflict setting.
The Perth-based company confirmed that the procedures followed a humanitarian shipment of the device to Ukraine in April 2025, and that surgeons are now successfully applying it in both primary and secondary nerve repair cases. Clinicians on the ground have provided strong, positive feedback, reinforcing confidence in the product’s clinical utility.
Remplir is designed to connect, protect and cap severed nerves caused by traumatic injury, a function that has become particularly relevant in battlefield medicine where complex nerve damage is common. Its physical characteristics have also proven advantageous in this environment, as the device can be stored at room temperature, transported easily and deployed without extensive logistical requirements.
A notable feature of the rollout has been the use of remote training. Ukrainian surgeons were trained via video by Orthocell’s key opinion leader, Dr Alex O’Beirne, demonstrating that the device can be adopted effectively even under constrained, high-pressure conditions. The company said this approach highlights both the accessibility and practicality of the technology in challenging environments.
Orthocell managing director Paul Anderson emphasised the broader significance of the deployment, stating, “In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant.” He added that “The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution.”
The company is continuing to engage with Ukrainian medical teams to monitor patient outcomes and gather clinical data, which is expected to inform future discussions with defence organisations worldwide. This expansion into military and trauma settings reflects a broader strategic opportunity for Orthocell as it seeks to position Remplir as a versatile nerve repair solution across both civilian and defence healthcare systems.
Orthocell also acknowledged the role of Ukraine’s ambassador to Australia, Vasyl Myroshnychenko, in facilitating coordination with local stakeholders, underscoring the collaborative effort behind the deployment.